Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
Eurobio Scientific→CareDx Lab Products division
Apr 16, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Totaligent, Inc. entered into a definitive agreement dated April 10, 2026 with Ivan Klarich. The agreement is tied to integrating Aetherium Medical’s assets into a joint venture with GloMed Solutions.
The Aetherium Medical platform is described as an infrastructure layer for AI-enabled biologic therapies, using cold-chain logistics, turnkey commercialization, and clinical-partner enablement across Asia-Pacific medical-tourism channels. The foundational operating business behind the platform has generated approximately $10 million in annual revenue and has been profitable for more than 15 years, supported by a proprietary network of more than 20 key opinion leaders and specialty clinics. The agreement states that Don Heath receives no compensation, equity, or other consideration under this agreement, with any Heath arrangements governed by a separate definitive agreement.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Eurobio Scientific→CareDx Lab Products division
Apr 16, 2026
Quvara Medical→Becton Dickinson
Apr 15, 2026
Parkview Health→Witham Health Services
Apr 15, 2026
Surgery Partners→Preferred Vascular Group
Apr 15, 2026
Sectra→Oxipit
Apr 15, 2026